Clinical Trial

Three-Vessel Versus Unilateral Antegrade Cerebral Perfusion in Emergency Total Arch Replacement for Acute Type A Aortic Dissection

Study acronym: MACP
Completed
View on ClinicalTrials.gov →
Summary
This single-centre retrospective observational cohort study describes the technical feasibility of direct three-vessel antegrade cerebral perfusion, designated modified antegrade cerebral perfusion (MACP), during emergency total arch replacement for acute type A aortic dissection. MACP delivers antegrade cerebral perfusion directly to the brachiocephalic, left common carotid, and left subclavian arteries. Outcomes are summarised descriptively and compared exploratorily with unilateral right axillary antegrade cerebral perfusion (uACP). Because perfusion strategy and treating surgeon were completely confounded, the comparative analyses are intended only to contextualise the technical experience and generate hypotheses.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-20; most recent amendment 2026-06-28.
Trial Details
NCT Number NCT07043777
Lead Sponsor China Medical University Hospital
Conditions Acute Type A Aortic Dissection
Enrollment 201 participants
Start Date 2021-01-01
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-01